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Since their widespread introduction into clinical practice in
the 1980s, statins have proven to be one of the most effective
treatments to reduce morbidity and mortality in patients
with vascular disease (1) and now represent one of the most
prescribed drug classes in the world. Despite this, the
mechanism whereby statins reduce vascular risk—whether it
is exclusively via cholesterol lowering, or whether there
might be beneficial effects mediated by non-lipid metabo-
lites that are also altered during statin therapy—remains
unclear. Given that vascular biology and physiology are
improved in pig, monkey, and mouse models of statin
treatment, wherein cholesterol levels do not change at all or
even rise (2), there is at least prima facie evidence that the
benefit of statins may extend beyond simple alteration in
lipid levels.
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A plethora of recent data has outlined many of the
beneficial effects that statin therapy may have on athero-
thrombotic processes (1). These include inhibitory effects on
monocyte adhesion to endothelial cells and platelet aggre-
gation, reduction of plaque inflammation, attenuation of
arterial wall hypoxia, and enhanced release of endothelium-
derived vasodilators such as nitric oxide (NO).
Indeed, as statin therapy is associated with greater im-
provements in clinical outcomes than improvements in the
degree of structural stenosis, it has been suggested that
statin-related benefits in vascular function may be a key
mechanism of the observed benefits of these drugs (3).
In this context, the current study of Binggeli et al. (4),
published in this issue of the Journal, demonstrates another
potentially beneficial effect of statin therapy on vascular
function, with several different drugs in this class, by
enhancing post-ischemic hyperemia in the skin circulation
of hypercholesterolemic patients. Although this is not of
direct clinical relevance per se, the authors suggest that these
data are consistent with a statin-related increase in endo-
thelial prostaglandin release, which may in turn have ben-
eficial effects on vascular function in other territories.
Furthermore, Binggeli et al. (4) propose that measurement
of post-ischemic hyperemia in the skin circulation could
prove to be a useful monitoring test for endothelial dysfunc-
tion, potentially suitable for use in clinical practice.
This study is therefore provocative and hypothesis-
generating; however, further work needs to be done before
accepting that the observed effect of statins in improving
skin hyperemia is actually prostaglandin-mediated or that
this non-invasive test will prove to be a useful clinical
method for assessing early vascular dysfunction.
Regarding mechanism, the vascular responses to ischemia
followed by reactive hyperemia are clearly complex, involv-
ing myogenic, neurogenic, and vasculogenic components,
mediated by a variety of metabolic alterations and factors
such as acidosis, hypoxia, adenosine, and NO (5). Although
Binggeli et al. (4) have shown that inhibition of prostaglan-
din synthesis decreases hyperemic skin flow by approxi-
mately 30% in healthy young adults, and thus is an impor-
tant contributor to the hyperemic response in skin, they
have not yet demonstrated that the statin-related improve-
ment in hypercholesterolemic subjects was actually due to
enhanced prostanoid release or bioavailability. In fact, as
prostaglandins are synthesized by many cells other than
endothelium (6), the contribution of the endothelium to
post-ischemic hyperemia in the skin remains uncertain.
Previous research has demonstrated that the arterial
endothelium does in general appear to be a very important
player in the regulation of blood flow as well as in the
maintenance of vascular health. By contrast, abnormal
endothelial function appears to be a key event in the
development of atherosclerosis and subsequently in deter-
mining cardiovascular risk (3,7). As normal endothelial
functions include thromboresistance, inhibition of mono-
cyte adhesion to the vessel wall, inhibition of smooth muscle
proliferation, and maintenance of tonic vasodilation, it is
hardly surprising that dysfunction of this important cell
layer might predispose patients to pathologic conditions
characterized by vasoconstriction, plaque development, and
excessive thrombosis. One of the key mediators in normal
endothelial function (interalia) is NO, which has a variety of
atheroprotective effects beyond mere vasodilation (3).
It has been known for several years that impaired
endothelium-dependent dilation in the systemic arteries can
be observed in children and young adults at risk of athero-
sclerosis before plaque development (8) and that endothelial
dysfunction in the epicardial coronary arteries can lead to
abnormal vasoconstriction and myocardial ischemia (7).
Furthermore, impaired endothelial function in the micro-
circulation has been associated with hypertension and mi-
crovascular angina (9). As several non-invasive or minimally
invasive techniques have recently been described to allow
the study of endothelial function in vivo, such tests have
been used by many clinical research groups to define sub-
jects at risk of atherosclerosis. Importantly, endothelial
dysfunction in high-risk subjects appears to be at least
partially reversible by certain therapeutic strategies, such as
statin or angiotensin-converting enzyme inhibitor therapy
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(10), that are also associated with improved clinical out-
comes (11). Thus, endothelial function testing has been
widely used to assess potentially anti-atherogenic or anti-
ischemic therapies by serial examination of arterial reactivity
before and after intervention.
The recent demonstration that endothelial dysfunction is
associated with adverse clinical outcomes in a variety of
settings (12), such as obstructive and non-obstructive cor-
onary disease and hypertension, has given further impetus to
the search for a widely applicable and clinically useful test of
endothelial function and dysfunction. The relevance of such
a test might include the identification of high-risk subjects
in a variety of clinical settings, such as primary prevention,
evaluation of patients with chest pain, and/or pre-operative
assessment of cardiovascular risk.
Despite this, the search for a simple non-invasive and
reproducible test of endothelial function has proven difficult.
Invasive catheterization of the coronary or indeed peripheral
arteries with the infusion of vaso-active substances such as
acetylcholine and nitrates (12) is a valuable research tool for
studying endothelial and smooth muscle function in vivo
but is clearly unsuitable for use in routine clinical practice.
The most widely used non-invasive test for arterial endo-
thelial health has been the ultrasound-based measurement
of flow-mediated dilation (FMD) in systemic vessels such as
the brachial artery (13). Flow-mediated dilation can be
measured accurately and reproducibly and is mainly medi-
ated by the release of endothelial NO. Also, there is good
correlation between FMD in the peripheral and coronary
arteries (14). Nevertheless, measuring FMD is technically
difficult and therefore somewhat operator-dependent; the
test is poorly standardized between different laboratories,
and FMD may show important fluctuations throughout the
day and after meals. Despite recent attempts to automate
analysis of arterial FMD and despite the publication of
guidelines for this procedure (13), much work needs to be
done before FMD measurement can be accepted as a widely
applicable diagnostic test.
In this context, the suggestion by Binggeli et al. (4) that
post-ischemic hyperemia in the skin circulation might be a
monitoring test of endothelial dysfunction for clinical prac-
tice requires careful scrutiny. Firstly, as noted above, it is
unclear whether hyperemia in the skin is an endothelium-
dependent response at all. Secondly, even if it is endothe-
lially mediated, this phenomenon appears not to be depen-
dent on NO. As NO mediates many of the important
anti-atherogenic effects of the vascular endothelium, this
would be a disadvantage to such a test. Furthermore, skin
hyperemia appears to be a test of microcirculatory responses,
which to date have not been correlated well with large-vessel
disease, the level of the circulation that is affected by
atherosclerosis. The relationship between the behavior of
skin microvessels and those in skeletal and cardiac muscle is
as yet unclear, and the reproducibility of skin hyperemia
may be relatively poor, with a coefficient of variation of 21%
documented in healthy controls (4).
Other aspects of endothelial function, apart from
endothelium-dependent dilation, have recently been exam-
ined in vivo. Serum levels of soluble cell adhesion molecules,
such as ICAM-1 and VCAM-1, are thought to reflect risk
by indicating increased endothelial adhesiveness (15). En-
dothelial release of tissue plasminogen activator has also
been measured in health and disease (16), as have serum
levels of von Willebrand factor, thought to be released by
dysfunctional endothelial cells (15).
There is little doubt that an effective test for vascular
endothelial function would be a tremendous advance in
diagnosing cardiovascular risk and in monitoring responses
to treatment. Such a test ideally should be non-invasive,
safe, and reproducible; it should distinguish between sub-
jects with and without atherosclerosis, and it should be
predictive of future events, when added to traditional
risk-factor based predictive models. At this stage, no such
test exists. Nevertheless, with the imaginative approach
taken by groups such as Binggeli et al. (4) and the rapid pace
of development of understanding endothelial function at
both a scientific and a technical level, clinical testing of
endothelial function should become possible in the near
future.
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